Cipla Limited (NSE:CIPLA)
India
· Delayed Price · Currency is INR 1,484.00
-14.10 (-0.94%)
Jun 19, 2025, 3:30 PM IST
Cipla Revenue
In the fiscal year ending March 31, 2025, Cipla had annual revenue of 271.45B INR with 6.30% growth. Cipla had revenue of 65.98B in the quarter ending March 31, 2025, with 6.89% growth.
Revenue
271.45B
Revenue Growth
+6.30%
P/S Ratio
4.46
Revenue / Employee
9.78M
Employees
27,764
Market Cap
1,210.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 271.45B | 16.09B | 6.30% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
| Fortis Healthcare | 77.83B |
Cipla News
- 4 weeks ago - Citi maintains ‘Buy’ on Cipla; sees 21.5% upside despite rising competition in Abraxane generic - Business Upturn
- 4 weeks ago - Nifty 50 top gainers today, May 21: Bharat Electronics, Tata Steel, Cipla, HDFC Life, Bajaj Finserv and more - Business Upturn
- 5 weeks ago - Bharti Airtel, Tata Motors & more: Top stocks on brokers' radar today - The Times of India
- 5 weeks ago - Nifty 50 top losers today, May 14: Cipla, Asian Paints, Tata Motors, Kotak Mahindra Bank, NTPC and more - Business Upturn
- 5 weeks ago - Nomura maintains ‘Buy’ on Cipla, target price Rs 1,760; sees steady FY26 outlook despite Q4 miss - Business Upturn
- 5 weeks ago - Cipla Q4 profit jump 30% to Rs 1,222 crore; Board approves Rs 16 per share dividend - The Times of India
- 5 weeks ago - Cipla Q4 Results: Board declares Rs 16 per share dividend, includes Rs 3 special payout - Business Upturn
- 5 weeks ago - Cipla Q4 Results: Revenue jumps 9% YoY to Rs 6,729 crore, Net Profit up 30% YoY - Business Upturn